Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	Checkpoint Therapeutics	Medicenna Therapeutics	Sierra Oncology	Lannett	Immutep
Symbol	NASDAQ:CKPT	NASDAQ:MDNA	NASDAQ:SRRA	NYSE:LCI	NASDAQ:IMMP
Price Information
Current Price	$2.38	$3.41	$17.60	$4.56	$3.54
52 Week Range	Buy	Buy	Buy	Hold	Buy
MarketRank™
Overall Score	1.2	0.7	1.8	2.1	1.3
Analysis Score	3.5	3.5	3.5	3.0	3.5
Community Score	2.6	0.0	2.6	2.6	2.9
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	0.0	0.0	2.5	2.5	0.0
Earnings & Valuation Score	0.0	0.0	0.6	2.5	0.0
Analyst Ratings
Consensus Recommendation	Buy	Buy	Buy	Hold	Buy
Consensus Price Target	$17.67	$10.00	$28.00	$8.50	$7.00
% Upside from Price Target	642.30% upside	193.26% upside	59.09% upside	86.40% upside	97.74% upside
Trade Information
Market Cap	$179.01 million	$182.60 million	$217.36 million	$188.99 million	$229.65 million
Beta	1.66	1.39	1.31	1.31	2.23
Average Volume	1,288,895	206,347	31,304	583,521	2,077,797
Sales & Book Value
Annual Revenue	$1.71 million	N/A	N/A	$545.74 million	$4.92 million
Price / Sales	104.68	N/A	N/A	0.35	46.68
Cashflow	N/A	N/A	N/A	$1.71 per share	N/A
Price / Cash	N/A	N/A	N/A	2.66	N/A
Book Value	$0.34 per share	$0.77 per share	$8.93 per share	$7.51 per share	$0.57 per share
Price / Book	7.00	N/A	N/A	0.61	6.21
Profitability
Net Income	$-24,710,000.00	$-6,220,000.00	$-88,280,000.00	$-33,370,000.00	$-9,040,000.00
EPS	($0.70)	($0.19)	($19.52)	$1.07	N/A
Trailing P/E Ratio	N/A	N/A	N/A	N/A	0.00
Forward P/E Ratio	N/A	N/A	N/A	4.90	∞
P/E Growth	N/A	N/A	N/A	N/A	N/A
Net Margins	-2,032.05%	N/A	N/A	-5.09%	N/A
Return on Equity (ROE)	-100.54%	-40.19%	-55.08%	12.62%	N/A
Return on Assets (ROA)	-75.09%	-37.66%	-45.75%	3.39%	N/A
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	N/A	N/A	N/A	1.96%	0.26%
Current Ratio	6.64%	26.75%	14.99%	2.02%	9.26%
Quick Ratio	6.64%	26.75%	15.00%	1.30%	9.26%
Ownership Information
Institutional Ownership Percentage	18.75%	3.90%	62.32%	86.12%	0.16%
Insider Ownership Percentage	7.80%	N/A	67.68%	13.63%	N/A
Miscellaneous
Employees	10	7	69	954	N/A
Shares Outstanding	75.21 million	53.55 million	12.35 million	41.45 million	64.87 million
Next Earnings Date	8/4/2021 (Estimated)	5/21/2021 (Estimated)	8/5/2021 (Estimated)	8/25/2021 (Estimated)	N/A
Optionable	Not Optionable	Not Optionable	Optionable	Optionable	Not Optionable

Source	Headline
	Keep on Avoiding Nio Stock, as Signs Point to Even Lower Prices - Report Door reportdoor.com - May 16 at 12:32 PM
	Immune Checkpoint Inhibitors Market is Likely to Increase at a Significantly High CAGR during Forecast Period 2027 – Clark County Blog - Clark County Blog clarkcountyblog.com - May 13 at 3:58 PM
	Latest Insights On Immune Checkpoint Inhibitors Industry. Major Players included in the report are Bristol Myer Squibb, AstraZeneca, Merck & Co., Roche / Genentech, Incyte Corporation, etc. – Clark County Blog - Clark County Blog clarkcountyblog.com - May 13 at 10:57 AM
	Global Parkinson's Disease Market Current Scenario Trends, Comprehensive Analysis and Regional Forecast to 2028\|\|GlaxoSmithKline Plc, Acorda Therapeutics, Inc, Amneal Pharmaceuticals LLC , Imugene Limited, Immutep – The Manomet Current - The Manomet Current manometcurrent.com - May 12 at 6:34 PM
	Immutep Operational Update - GlobeNewswire globenewswire.com - May 7 at 9:06 AM
	Immutep (NASDAQ:IMMP) Stock Passes Below 50-Day Moving Average of $3.23 americanbankingnews.com - May 7 at 3:40 AM
	Immutep - Operational Update - Finance News Network finnewsnetwork.com.au - May 6 at 11:04 PM
	Bristol Myers Squibb's Latest Data Could Help the Pharma Leapfrog Rival Merck - Nasdaq nasdaq.com - May 3 at 7:46 AM
	Immutep : Corporate Connect - Efti a highly sort after compound for mono & combo Cancer treatment - Marketscreener.com marketscreener.com - April 30 at 10:32 AM
	BMS's Cancer Trial Highlights Potential for Immune Checkpoint Inhibitors - Labiotech.eu labiotech.eu - April 29 at 8:01 AM
	Immutep (ASX:IMM) primed to present data at ASCO Annual Meeting - The Market Herald themarketherald.com.au - April 28 at 8:14 PM
	Immutep To Announce New TACTI-002 and INSIGHT-004 Data in Poster Presentations and Discussion at the ASCO 2021 Annual Meeting - GlobeNewswire globenewswire.com - April 28 at 3:14 PM
	Short Interest in Immutep Limited (NASDAQ:IMMP) Decreases By 64.7% americanbankingnews.com - April 28 at 5:46 AM
	What Type Of Shareholders Own The Most Number of Immutep Limited (ASX:IMM) Shares? - Yahoo Finance finance.yahoo.com - April 26 at 1:43 AM
	Immutep Receives A$1,155,055 R&D Tax Incentive - Yahoo Finance finance.yahoo.com - April 16 at 8:33 AM
	Immutep Receives A$1,155,055 R&D Tax Incentive finance.yahoo.com - April 16 at 8:33 AM
	Immutep Investor Update - Finance News Network finnewsnetwork.com.au - April 14 at 4:51 AM
	Why Prima is Creating DTC Solutions for Stress finance.yahoo.com - April 12 at 2:01 PM
	Immutep ADS Representing 10 Ord Shs (IMMP) is down 6.78% Friday In Premarket Trading - InvestorsObserver investorsobserver.com - April 9 at 8:48 AM
	IMMP Stock: The Big Patent News Boosting Immutep Today - InvestorPlace investorplace.com - April 9 at 12:07 AM
	Immutep Limited (IMMP) Stock Rises After FDA Designation - InvestorsObserver investorsobserver.com - April 9 at 12:07 AM
	Immutep jumps 13% after getting fast-track status for its drug to treat head and neck cancer - Markets Insider markets.businessinsider.com - April 9 at 12:07 AM
	Why Immutep Limited Stock Popped Today - The Motley Fool fool.com - April 9 at 12:07 AM
	Netflix Inks Multi-Year Deal With Sony Pictures - Nasdaq nasdaq.com - April 8 at 7:06 PM
	Why Immutep Limited Stock Popped Today fool.com - April 8 at 5:31 PM

Date	Company	Brokerage	Action
2/1/2021	Checkpoint Therapeutics	Cantor Fitzgerald	Reiterated Rating
9/29/2020	Checkpoint Therapeutics	HC Wainwright	Boost Price Target
7/15/2020	Checkpoint Therapeutics	LADENBURG THALM/SH SH	Reiterated Rating
12/27/2019	Checkpoint Therapeutics	Lake Street Capital	Reiterated Rating
12/17/2020	Medicenna Therapeutics	Oppenheimer	Initiated Coverage
8/24/2020	Medicenna Therapeutics	Brookline Capital Management	Reiterated Rating
8/24/2020	Medicenna Therapeutics	Bloom Burton	Reiterated Rating
11/6/2020	Sierra Oncology	Lifesci Capital	Reiterated Rating
2/28/2019	Sierra Oncology	Wedbush	Reiterated Rating
11/3/2020	Lannett	Raymond James	Reiterated Rating
8/27/2020	Lannett	Roth Capital	Boost Price Target
8/27/2020	Lannett	BMO Capital Markets	Reiterated Rating
9/18/2019	Lannett	SunTrust Banks	Boost Price Target
8/20/2018	Lannett	Craig Hallum	Downgrade
1/26/2021	Immutep	Alliance Global Partners	Boost Price Target
12/14/2020	Immutep	Maxim Group
9/28/2018	Immutep	B. Riley	Initiated Coverage

(Data available from 5/16/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources